Losartan reduces cardiac mass and improves coronary flow reserve in the spontaneously hypertensive rat

Journal of Hypertension

Volumn 14, Issue 5, 1996, Pages 645-653

  Kaneko, Kazuhiro ^a   Susic, Dinko ^a   Nunez, Eduardo ^a   Frohlich, Edward D ^a  

^a OCHSNER MEDICAL CENTER   (United States)

Author keywords

Angiotensin II receptor antagonist; Coronary circulation; Dipyridamole; Left ventricular hypertrophy; Regional hemodynamics; Systemic hemodynamics; Treadmill exercise

Indexed keywords

DIPYRIDAMOLE; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY HEMODYNAMICS; CORONARY VASCULAR RESISTANCE; HEART AFTERLOAD; HEART INDEX; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART WEIGHT; HEMODYNAMICS; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREADMILL EXERCISE;

EID: 0029977326     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199605000-00015     Document Type: Article

References (45)

1. Frohlich ED: Left ventricular hypertrophy: an independent risk factor. In Preventive Aspects of Coronary Heart Disease. Edited by Frohlich ED. Philadelphia: F.A. Davis Co.; 1990:85-94.
2. Kannel WB, Gordon T, Offutt D: Left ventricular hypertrophy by electrocardiogram: prevalence, incidence and mortality in the Framingham Study. Ann Intern Med 1960, 71:89-105.
3. Levy D, Garrison FJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echo-cardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990, 322:1561-1566.
4. Dellsperger KC, Marcus ML: Effects of left ventricular hypertrophy on the coronary circulation. Am J Cardiol 1990, 65:1504-1510.
5. Pfeffer MA, Pfeffer JM, Frohlich ED: Pumping ability of the hypertrophied left ventricle of the spontaneously hypertensive rat. Circ Res 1976, 38:423-429.
6. Pfeffer MA, Pfeffer JM, Frohlich ED: Cardiac function and morphology with aging in the spontaneously hypertensive rat. Am J Physiol 1979, 237:H461-H468.
7. Tomanek RJ: Response of the coronary vasculature to myocardial hypertrophy. J Am Coll Cardiol 1990, 15:528-533.
8. Susic D, Frohlich ED: Left ventricular hypertrophy: a pathophysiological and molecular biological perspective. Hypertens Res 1993, 16:163-177.
9. Frohlich ED, Horinaka S: Cardiac and aortic effects of angiotensin converting enzyme inhibitors. Hypertension 1991, 18 (suppl 11):2-7.
10. Frohlich ED, Sasaki O, Chien Y, Arita M: Changes in cardiovascular mass, left ventricular pumping ability and aortic distensibility after calcium antagonists in Wistar-Kyoto and spontaneously hypertensive rats. J Hypertens 1992, 10:1369-1378.
11. Pegram BL, Ishise S, Frohlich ED: Effects of methyldopa, clonidine and hydralazine on cardiac mass and hemodynamics in Wistar-Kyoto and spontaneously hypertensive rats. Circ Res 1982, 16:40-46.
12. Ando K, Frohlich ED, Chien Y, Pegram BL: Effects of quinapril on systemic and regional hemodynamics and cardiac mass in spontaneously hypertensive and Wistar-Kyoto rats. J Vasc Med Biol 1991, 3:117-123.
13. Linz W, Schaper J, Wiemer G, Albus U, Scholkens BA: Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats. Br J Pharmacol 1992, 107:970-975.
14. Gohlke P, Linz W, Scholkens BA, Kuwer T, Bortenbach S, Schnell A, et al.: Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension 1994, 23:411-418.
15. Scicli AG: Increases in cardiac kinins as a new mechanism to protect the heart. Hypertension 1994, 23:419-421.
16. Brunner HR, Nussberger J, Waeber B: Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system. J Hypertens 1993, 11 (suppl 3):S53-S58.
17. Bunkenburg B, Schnell C, Baum HP, Cumin F, Wood JM: Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hypertension 1991, 18:278-288.
18. Tofovic SP, Pong AS, Jackson EK: Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats. Hypertension 1990, 18:774-782.
19. Wong PC, Price WA, Chiu AT, Dunicia JV, Carini DJ, Wexler RR, et al.: Hypotensive action of DuP 753, and angiotensin II antagonist, in spontaneously hypertensive rats. Hypertension 1990, 15:459-468.
20. Mimran A, Targhett R, Laroche B: The hypertensive effects of captopril: evidence for an influence of kinins. Hypertension 1980, 2:732-737.
21. Nasjletti A, Colina-Chourio J, McGiff JC: Disappearance of bradykinin in the renal circulation of dogs. Circ Res 1975, 37:59-65.
22. Swartz SL, Williams GH, Hollenberg NK, Levine L, Dluhy RG, More JC: Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. J Clin Invest 1980, 65:1257-1264.
23. Timmermans PBMWM, Chiu AT, Herblin WF, Wong PC, Smith RD: Angiotensin II receptor subtypes. Am J Hypertens 1992, 5:406-410.
24. Soria F, Frohlich ED, Aristizabal D, Kaneko K, Kardon MB, Hunter J, et al.: Preserved cardiac performance after quinapril-induced left ventricular mass reversal in spontaneously hypertensive rats. J Hypertens 1994, 12:585-589.
25. Ishisa S, Pegram BL, Yamamoto J, Kitamura Y, Frohlich ED: Cardiac output and blood flow in conscious rats. Am J Physiol 1980, 239:H443-H449.
26. Kobrin I, Kardon MB, Oigman W, Pegram BL, Frohlich ED: Role of site of microsphere injection and catheter position on systemic and regional hemodynamics in rat. Am J Physiol 1984, 247:H35-H39.
27. Tomanek PJ, Wangler RD, Bauer CA: Prevention of coronary vasodilator reserve decrement in spontaneously hypertensive rats. Hypertension 1985, 7:533-540.
28. Wangler RD, Peters KG, Marcus ML, Tomanek RJ: Effects of duration and severity of arterial hypertension and cardiac hypertrophy on coronary vasodilator reserve. Circ Res 1982, 51:10-18.
29. Pfeffer MA, Pfeffer JM, Dunn FG, Nishiyama K, Tsuchiya M, Frohlich ED: Natural biventricular hypertrophy in normotensive rats. I. Physical and hemodynamic normotensive characteristics. Am J Physiol 1979, 236;H640-H643.
30. Sesoko S, Pegram BL, Kuwajima I, Frohlich ED: Hemodynamic studies in spontaneously hypertensive rats with congenital arteriovenous shunts. Am J Physiol 1982, 242:H722-H725.
31. Baker KM, Cherin MI, Wixson SK, Aceto JF: Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 1990, 28:H324-H332.
32. Dzau VJ, Re RN: Evidence of existence of renin in the heart. Circulation 1989, 75 (suppl 1):134-136.
33. 1 expression. Hypertension 1984, 23:587-592.
34. Kojima M, Shiojima I, Yamazaki T, Komura I, Yunzeng Z, Ying W, et al.: Angiotensin II receptor antagonist TCV-116 induces regression of left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocite hypertrophy in vitro. Circulation 1994, 89:2204-2211.
35. Mizuno K, Tani M, Hashimoto S, Niimura S, Sanada H, Watanabe H, et al.: Effect of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Life Sci 1992, 51:367-374.
36. Rockman HA, Wachhorst SP, Mao L, Ross J Jr: ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol 1994, 35:H2468-H2475.
37. Linz W, Schölkens BA, Ganten D: Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens [A] 1989, 11:1325-1350.
38. Rizoni D, Castellano M, Porteri E, Bettoni G: Effects of low and high doses of fosinopril on the structure and function of resistance arteries. Hypertension 1995, 26:118-123.
39. Fomes P, Richer C, Vacher E, Bruneval P, Giudicelli JF: Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 1993, 22:305-313.
40. Wong PC, Price WA, Chiu AT, Dunicia JV: In vivo pharmacology of DuP 753. Am J Hypertens 1991, 4 (suppl 2):288S-298S.
41. Strauer B, Schwartzkopf B, Motz W, Vogt M: Coronary vascular changes in the progression and regression of hypertensive heart disease. J Cardiovasc Pharmacol 1991, 18 (suppl 3):20-27.
42. Clozel JP, Véniant M, Hess P, Sprecher U: Effects of two angiotensin converting enzyme inhibitors and hydralazine on coronary circulation in hypertensive rats. Hypertension 1991, 18 (suppl II):8-14.
43. Anderson PG, Bishop SP, Digemess SB: Vascular remodeling and improvement of coronary reserve after hydralazine treatment in spontaneously hypertensive rats. Circ Res 1989, 65:1127-1136.
44. Braunwald E, Sarnoff SJ, Case RB: Hemodynamic determinants of coronary flow: effect of changes in aortic pressure and cardiac output on the relationship between myocardial oxygen consumption and coronary flow. Am J Physiol 1958, 192:157-163.
45. Frohlich ED: Clinical conference: hypertensive cardiovascular disease. A pathophysiological assessment. Hypertension 1984, 6:934-939.